Insider trade

Officer purchased ~$585 of BIIB shares in the open market

Traded Feb 12, 2026 · Filed Feb 18, 2026

BiogenBIIB

~$585
Reported value · 3 sh @ $195.035: 20K
Holds after · shares reported: +14.0%
stock since the trade · S&P 500 +12.1%, $195.50 → $222.82 on Oct 1

Why it stands out

Biogen's Head of Pharm Ops and Tech spent $585 of their very own money to buy Biogen shares.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 12, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 18, 2026

Officer<$25K

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$585

Shares × reported transaction price

Size band

<$25K

Rarity

Not enough history to judge

Confirmed open-market purchases by the same insider in the available history

Cluster activity

No other insider purchases within 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Size vs officer pay

This purchase equals less than 1% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($5.87M)

An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-28. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement

Timing vs results

6 days after results of Feb 6, 2026, 53 days before results of Apr 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $195.50 on Feb 12, 2026, within 3% of its 52-week high, after an 11% rise over the previous 30 trading days

52-week range $113.38 (Apr 10, 2025) to $201.18 (Feb 6, 2026), 94% of the way up, from 251 adjusted closes. 30 trading days earlier: $176.40 on Dec 30, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 23, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

Gray v. Biogen Inc., docket 1:24-cv-12691, via CourtListener (court records). Nature of suit 850, company named as first defendant